We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+3.9%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.35B
AUM Growth
-$238M
Cap. Flow
-$201M
Cap. Flow %
-14.89%
Top 10 Hldgs %
64.03%
Holding
94
New
18
Increased
13
Reduced
24
Closed
26

Top Buys

Rank Stock Value
1
INZY
Inozyme Pharma
INZY
+$50.4M
2
CMPI
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
+$46.2M
3
AMGN icon
Amgen
AMGN
+$27.7M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$19.8M
5
NCNA
NuCana
NCNA
+$18.1M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$84.7M
2
GILD icon
Gilead Sciences
GILD
+$31M
3
CHRS icon
Coherus Oncology
CHRS
+$27.9M
4
AMRN
Amarin Corp
AMRN
+$24.2M
5
MRK icon
Merck
MRK
+$21.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRSN
76
DELISTED
Mersana Therapeutics
MRSN
– –
-5,519
Closed -$3.23M
NTLA icon
77
Intellia Therapeutics
NTLA
$1.51B
– –
-57,500
Closed -$1.21M
OEF icon
78
PUT
iShares S&P 100 ETF
OEF
$19.5B
– –
-70,000
Closed -$10M
ORIC icon
79
Oric Pharmaceuticals
ORIC
$1.17B
– –
-17,369
Closed -$585K
PFE icon
80
CALL
Pfizer
PFE
$143B
– –
-184,450
Closed -$5.72M
PTCT icon
81
CALL
PTC Therapeutics
PTCT
$6.18B
– –
-60,000
Closed -$3.04M
QQQ icon
82
PUT
Invesco QQQ Trust
QQQ
$436B
– –
-30,000
Closed -$7.43M
RIGL icon
83
Rigel Pharmaceuticals
RIGL
$723M
– –
-33,970
Closed -$622K
SNDX icon
84
Syndax Pharmaceuticals
SNDX
$1.7B
– –
-91,964
Closed -$1.36M
VYNE icon
85
VYNE Therapeutics
VYNE
– –
-202
Closed -$1.26M
XLV icon
86
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$42.9B
– –
-150,000
Closed -$15M
XNTK icon
87
PUT
State Street SPDR NYSE Technology ETF
XNTK
$1.94B
– –
-150,000
Closed -$16.8M
ITCI
88
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-220,000
Closed -$5.65M
MRTX
89
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-8,072
Closed -$922K
CNST
90
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
– –
-207,087
Closed -$6.22M
PRNB
91
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
– –
-1,417,258
Closed -$84.7M
HZNP
92
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-252,958
Closed -$14.1M
1 2 3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q3 2020 Portfolio in Review

As of Q3 2020, Sofinnova Investments held 94 positions worth $1.35B, down 15% from $1.59B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Sofinnova Investments withdrew a net $201M in Q3 2020, closing 26 positions and reducing 24 holdings. Its most notable exit was Principia Biopharma Inc. Common Stock, an estimated $84.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Inozyme Pharma worth $53.3M.

  • Sofinnova Investments's largest Q3 2020 buy was Inozyme Pharma: 2,028,308 shares worth $53.3M.
  • Sofinnova Investments added most to BioMarin Pharmaceuticals in Q3 2020, an estimated $19.8M increase.
  • Sofinnova Investments's biggest Q3 2020 reduction was Coherus Oncology, cutting an estimated $27.9M.
  • Sofinnova Investments fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $84.7M.
  • Sofinnova Investments's ten largest holdings make up 64% of its $1.35B portfolio in Q3 2020.
  • Sofinnova Investments opened 18 new positions and closed 26 in Q3 2020.
  • Sofinnova Investments's portfolio value fell 15% quarter-over-quarter to $1.35B.

Based on Sofinnova Investments's 13F filing for Q3 2020, filed 13 Nov 2020.